This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
One-third of patients with intracerebral hemorrhage (ICH) are dead within 1 month of symptom onset, and only 20% regain functional independence.1 In a recent Phase IIB study, recombinant Factor VIIa (rFVIIa) given within 4 hours after the onset of ICH significantly reduced hematoma growth and improved clinical outcomes; this effect is being evaluated in a Phase III trial.2 Enthusiasm for the use of rFVIIa is tempered by safety concerns. An increased frequency of thromboembolic complications, notably arterial ischemic events, among patients with ICH treated with rFVIIa has been observed. We report our open-label experience with rFVIIa used within an institution-approved protocol and the occurrence of posthemorrhagic hydrocephalus as an unexpected complication.
rFVIIa was administered at a dose of 40 μg/kg body weight to nine patients with ICH diagnosed by CT scan within 3 hours from symptom onset. The inclusion and exclusion criteria for administration of rFVIIa were …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa
- Reply from the Authors
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
